cardiac
transplant
endstag
heart
failur
reject
immunosuppress
heart
transplant
indic
patient
heart
failur
despit
optim
medic
devic
therapi
manifest
intract
angina
refractori
heart
failur
intract
ventricular
arrhythmia
evalu
heart
transplant
focus
assess
presenc
optim
medic
manag
stabil
extracardiac
function
adequ
complianc
caregiv
support
standard
immunosuppress
transplant
consist
tripledrug
therapi
corticosteroid
calcineurin
inhibitor
commonli
tacrolimu
antiprolif
agent
commonli
mycophenol
mofetil
treatment
reject
progress
aggress
patient
clinic
statu
worsen
rang
oral
corticosteroid
bolu
taper
intraven
puls
corticosteroid
cytolyt
therapi
antithymocyt
globulin
intraven
immun
globulin
plasmapheresi
circulatori
support
inotrop
therapi
intraaort
balloon
counterpuls
extracorpor
membran
oxygen
major
longterm
complic
heart
transplant
cardiac
allograft
vasculopathi
infect
malign
cardiol
clin
http
dx
despit
advanc
pharmacolog
devic
treatment
chronic
heart
failur
longterm
morbid
mortal
remain
unaccept
high
mani
patient
progress
endstag
heart
failur
mortal
patient
symptomat
heart
failur
approach
may
high
year
endstag
patient
last
decad
cardiac
transplant
becom
prefer
therapi
select
patient
endstag
heart
diseas
approxim
heart
transplant
perform
annual
unit
state
accord
registri
intern
societi
heart
lung
transplant
median
surviv
patient
transplant
current
year
year
surviv
first
year
fig
signific
improv
medic
therapi
heart
failur
purpos
articl
provid
overview
heart
transplant
current
era
focus
evalu
process
heart
transplant
physiolog
transplant
heart
immunosuppress
regimen
earli
longterm
complic
relev
financi
relationship
disclos
divis
cardiolog
cedarssinai
heart
institut
lo
angel
ca
usa
major
indic
heart
transplant
heart
failur
angina
ventricular
arrhythmia
refractori
maxim
medic
therapi
common
indic
heart
transplant
refractori
heart
failur
angina
alon
often
consid
indic
transplant
absenc
heart
failur
clear
surviv
patient
improv
heart
transplant
intract
ventricular
arrhythmia
commonli
refer
vt
storm
may
merit
heart
transplant
evalu
often
urgent
list
given
associ
hemodynam
compromis
rel
scarciti
donor
organ
make
essenti
determin
whether
patient
truli
refractori
maxim
medic
therapi
requir
heart
transplant
fig
object
measur
may
help
stratifi
sever
ill
includ
cardiopulmonari
exercis
stress
test
right
heart
catheter
cardiopulmonari
exercis
stress
test
measur
maxim
oxygen
consumpt
vo
max
proport
cardiac
output
compens
patient
vo
max
mlkgmin
adequ
effort
indic
poor
surviv
next
year
indic
proceed
evalu
adequ
effort
defin
patient
achiev
anaerob
threshold
point
co
product
exce
consumpt
indic
respiratori
exchang
ratio
rer
perform
right
heart
catheter
patient
euvolem
help
assess
degre
fix
postcapillari
pulmonari
hypertens
cardiac
output
rest
cardiac
index
valu
less
lminm
suggest
poor
reserv
need
transplant
evalu
major
contraind
heart
transplant
medic
socialpsycholog
standard
test
heart
transplant
evalu
outlin
box
potenti
contraind
describ
detail
tabl
mani
factor
absolut
need
consid
context
sever
patient
heart
diseas
associ
comorbid
donor
heart
place
recipi
affer
heart
central
nervou
system
effer
central
nervou
system
heart
nerv
suppli
lost
loss
affer
nerv
suppli
mean
recipi
experi
angina
therefor
chest
discomfort
heart
transplant
recipi
especi
earli
transplant
like
caus
coronari
ischemia
coronari
ischemia
like
present
chest
discomfort
standard
practic
annual
angiogram
surveil
transplant
coronari
arteri
diseas
direct
consequ
lack
affer
nerv
suppli
transplant
heart
consequ
loss
effer
nerv
relat
loss
vagal
tone
postganglion
direct
releas
norepinephrin
store
respons
exercis
loss
vagal
tone
heart
transplant
recipi
higher
normal
rest
heart
rate
around
beat
per
minut
lack
effer
nerv
also
mean
transplant
recipi
must
reli
circul
catecholamin
respond
exercis
blunt
heart
rate
respons
exercis
similarli
exercis
heart
rate
return
baselin
slowli
gradual
declin
circul
catecholamin
concentr
baselin
heart
transplant
recipi
lack
baroreceptor
reflex
reli
intact
baroreceptor
sympathet
parasympathet
innerv
thu
heart
transplant
recipi
suscept
orthostasi
carotid
sinu
massag
break
reentrant
tachycardia
patient
nevertheless
heart
transplant
recipi
often
experi
reinnerv
heart
return
angina
improv
exercis
toler
decreas
rest
heart
rate
process
inconsist
among
patient
although
tend
increas
time
cardiac
drug
effect
denerv
heart
lack
vagal
tone
digoxin
littl
effect
sinoatri
atrioventricular
conduct
veloc
achiev
rate
control
transplant
heart
develop
atrial
fibril
howev
inotrop
effect
digoxin
persist
transplant
similarli
parasympatholyt
effect
atropin
increas
heart
rate
transplant
heart
owe
lack
baroreceptor
reflex
vasodil
nifedipin
hydralazin
caus
reflex
tachycardia
lack
postganglion
sympathet
nerv
transplant
heart
result
increas
receptor
densiti
thu
sensit
sympathet
agonist
antagonist
clinic
often
seen
bblocker
heart
transplant
recipi
often
exagger
fatigu
occasion
bradycardia
respons
administr
bblocker
especi
exercis
purpos
purpos
induct
therapi
origin
induc
toler
graft
although
goal
realiz
benefit
induct
therapi
includ
mark
reduct
reject
first
week
transplant
abil
delay
introduct
calcineurin
inhibitor
prevent
worsen
renal
dysfunct
disadvantag
induct
therapi
includ
increas
risk
infect
risk
malign
rate
late
reject
therapi
complet
year
reject
rate
patient
receiv
induct
usual
similar
receiv
induct
regimen
induct
therapi
includ
cytolyt
agent
antithymocyt
globulin
receptor
antagonist
dacluzimab
fig
howev
despit
widespread
use
random
trial
cytolyt
agent
induct
therapi
perform
heart
transplant
recipi
retrospect
evalu
larg
multiinstitut
databas
suggest
cytolyt
therapi
reduc
risk
earli
reject
increas
risk
infect
random
trial
induct
therapi
dacluzimab
heart
transplant
recipi
recipi
less
reject
increas
risk
death
infect
blind
natur
studi
patient
receiv
antagonist
cytolyt
induct
therapi
base
result
induct
therapi
standard
practic
mani
center
instead
therapi
often
antithymocyt
globulin
may
reserv
patient
highest
risk
reject
includ
patient
highli
sensit
donorspecif
antibodi
signific
renal
dysfunct
delay
calcineurin
inhibit
advis
purpos
mainten
immunosuppress
therapi
prevent
longterm
reject
transplant
recipi
tripledrug
therapi
commonli
consist
steroid
calcineurin
inhibitor
cyclosporin
tacrolimu
antiprolif
agent
azathioprin
mycophenol
mofetil
mmf
tabl
special
situat
prolifer
signal
inhibitor
psi
sirolimu
everolimu
may
replac
calcineurin
inhibitor
antiprolif
agent
although
optim
mainten
immunosuppress
regimen
yet
identifi
evid
regimen
may
tailor
individu
patient
detail
mechan
action
corticosteroid
potent
immunosuppress
antiinflammatori
agent
see
fig
corticosteroid
diffus
freeli
across
cell
membran
ultim
alter
express
gene
involv
immun
inflammatori
tabl
contraind
heart
transplant
age
rel
contraind
depend
associ
comorbid
obes
bodi
mass
index
bmi
kgm
recommend
center
toler
bmi
kgm
malign
activ
neoplasm
except
nonmelanoma
skin
cancer
absolut
contraind
cancer
low
grade
prostat
remiss
may
accept
consult
oncologist
pulmonari
hypertens
inabl
achiev
pulmonari
vascular
resist
vasodil
inotrop
therapi
contraind
patient
may
benefit
longterm
unload
ventricular
assist
devic
diabet
uncontrol
diabet
associ
signific
endorgan
damag
absolut
contraind
renal
dysfunct
due
diabet
may
absolut
contraind
peripher
vascular
diseas
sever
diseas
amen
revascular
absolut
contraind
infect
human
immunodefici
viru
hepat
c
absolut
contraind
center
substanc
use
mo
abstin
smoke
alcohol
illicit
drug
requir
critic
ill
patient
consult
psychiatri
social
work
essenti
psychosoci
issu
noncompli
lack
caregiv
support
dementia
absolut
contraind
mental
retard
may
rel
contraind
respons
affect
number
distribut
function
leukocyt
administr
corticosteroid
first
given
intraven
bolu
methylprednisolon
transplant
surgeri
oral
prednison
given
standard
taper
differ
variou
institut
author
center
patient
receiv
prednison
mg
twice
daili
decreas
mg
increment
patient
mg
twice
daili
month
transplant
patient
start
prednison
taper
month
prednison
reduc
mg
daili
month
decreas
mg
daili
program
patient
reject
first
month
candid
wean
prednison
complet
year
transplant
side
effect
steroid
therapi
signific
shortterm
longterm
side
effect
shortterm
side
effect
includ
tremor
emot
labil
easi
bruisabl
poor
wound
heal
weight
gain
fluid
retent
hyperglycemia
longterm
advers
effect
includ
hypertens
cataract
ulcer
diseas
risk
infect
osteoporosi
longterm
administr
steroid
may
result
chronic
adren
suppress
adren
insuffici
follow
steroid
taper
stress
infect
surgeri
mechan
action
calcineurin
inhibitor
becom
cornerston
mainten
therapi
calcineurin
inhibitor
use
clinic
practic
cyclosporin
tacrolimu
act
block
calciumactiv
calcineurin
see
fig
cyclosporin
bind
cyclophilin
tacrolimu
bind
fkbind
protein
complex
bind
calcineurin
dephosphoryl
nuclear
factor
activ
cell
nfat
dephosphoryl
nfat
bind
specif
dna
site
ultim
inhibit
transcript
cytokin
clinic
trial
tacrolimu
compar
cyclosporin
sever
random
clinic
trial
tacrolimu
cyclosporin
demonstr
compar
surviv
heart
transplant
tacrolimu
may
associ
less
treat
reject
tacrolimu
current
calcineurin
inhibitor
choic
mainten
immunosuppress
therapi
administr
either
cyclosporin
tacrolimu
given
oral
immedi
follow
surgeri
cyclosporin
dose
titrat
achiev
target
therapeut
trough
level
ngml
long
term
cyclosporin
dose
reduc
achiev
target
trough
level
ngml
tacrolimu
titrat
achiev
target
therapeut
level
ngml
initi
postop
longer
term
dose
reduc
achiev
target
level
ngml
center
higher
level
tacrolimu
target
attempt
reduc
need
corticosteroid
antiprolif
agent
side
effect
cyclosporin
caus
nephrotox
hypertens
dyslipidemia
neurolog
toxic
hypertrichosi
gingiv
hyperplasia
tacrolimu
similar
sideeffect
profil
caus
hypertrichosi
gingiv
hyperplasia
fact
alopecia
may
occur
hyperglycemia
neurolog
toxic
common
tacrolimu
mechan
action
azathioprin
mmf
antiprolif
agent
use
commonli
heart
transplant
see
fig
azathioprin
ultim
convert
cell
purin
analogu
incorpor
dna
thu
inhibit
synthesi
prolifer
b
lymphocyt
mmf
inhibitor
key
enzym
de
novo
synthesi
guanin
nucleotid
prolifer
lymphocyt
depend
clinic
trial
multicent
random
clinic
trial
compar
azathioprin
mmf
combin
cyclosporin
steroid
demonstr
mmftreat
patient
improv
surviv
less
reject
less
cardiac
allograft
vasculopathi
time
mmf
thu
antimetabolit
choic
standard
mainten
therapi
heart
transplant
recipi
administr
either
azathioprin
mmf
given
oral
immedi
transplant
azathioprin
dose
rang
mg
daili
mmf
usual
prescrib
mg
twice
daili
although
dose
reduct
may
necessari
gastrointestin
upset
leukopenia
though
standard
trough
level
mycophenol
acid
often
check
goal
level
greater
mgml
major
side
effect
azathioprin
myelosuppress
furthermor
azathioprin
prescrib
allopurinol
allopurinol
inhibit
xanthin
oxidas
lead
increas
accumul
metabolit
azathioprin
greater
chanc
myelosuppress
major
side
effect
mmf
includ
nausea
vomit
diarrhea
usual
respond
decreas
dosag
switch
sustainedreleas
prepar
prolifer
signal
inhibitor
mechan
action
psi
sirolimu
everolimu
although
sirolimu
approv
us
food
drug
administr
use
heart
transplant
recipi
everolimu
approv
patient
kidney
liver
transplant
agent
inhibit
kinas
target
rapamycin
see
fig
ultim
inhibit
prolifer
b
lymphocyt
smooth
muscl
cell
endotheli
cell
clinic
trial
de
novo
transplant
recipi
compar
azathioprin
sirolimu
demonstr
less
reject
less
cardiac
allograft
vasculopathi
measur
intravascular
ultrasonographi
first
year
howev
de
novo
patient
receiv
sirolimu
like
develop
renal
dysfunct
pneumonia
impair
wound
heal
less
like
develop
cytomegaloviru
cmv
infect
similarli
everolimu
compar
azathioprin
mycophenol
de
novo
heart
transplant
recipi
less
reject
cardiac
allograft
vasculopathi
viral
infect
worsen
renal
function
higher
incid
bacteri
infect
furthermor
highdos
everolimu
mg
daili
associ
increas
mortal
arm
prematur
termin
lowdos
everolimu
mg
daili
associ
higher
mortal
administr
base
result
aforement
trial
sirolimu
everolimu
rare
start
de
novo
heart
transplant
author
institut
sirolimu
everolimu
substitut
mmf
patient
reject
cardiac
allograft
vasculopathi
neoplasm
viral
infect
cmv
psi
may
also
use
place
calcineurin
inhibitor
amelior
renal
dysfunct
side
effect
major
side
effect
psi
includ
hypertriglyceridemia
myelosuppress
fluid
retent
diarrhea
fatigu
oral
ulcer
side
effect
respond
reduct
dose
although
mani
patient
toler
psi
advers
effect
diagnosi
transplant
reject
remain
one
major
caus
death
heart
transplant
reject
frequent
first
month
heart
transplant
declin
thereaft
clinic
symptom
reject
often
vagu
routin
test
reject
absenc
symptom
standard
practic
unlik
renal
liver
transplant
laboratori
marker
reject
heart
transplant
thu
endomyocardi
biopsi
standard
approach
routin
surveil
reject
endomyocardi
biopsi
commonli
perform
outpati
set
via
right
intern
jugular
venou
approach
fluoroscop
guidanc
seriou
complic
occur
case
includ
tricuspid
valv
injuri
cardiac
perfor
result
tamponad
although
time
biopsi
vari
center
center
gener
biopsi
perform
frequent
earli
transplant
less
frequent
time
goe
author
center
year
biopsi
perform
heart
transplant
recipi
develop
symptom
sign
reject
purpos
endomyocardi
biopsi
assess
myocardi
damag
form
cellular
antibodymedi
reject
diagnosi
cellular
reject
made
accord
revis
intern
societi
heart
lung
transplant
ishlt
grade
scale
publish
simplifi
prior
classif
biopsi
classifi
grade
r
reject
chang
grade
r
mild
reject
grade
grade
r
moder
reject
grade
grade
r
sever
reject
grade
grade
r
higher
reject
biopsi
consid
signific
merit
treatment
discuss
detail
next
section
diagnosi
antibodymedi
reject
less
straightforward
achiev
greater
standard
consensu
confer
propos
classif
endomyocardi
biopsi
grade
base
presenc
histolog
immunolog
find
consist
antibodymedi
reject
fig
histolog
find
includ
endotheli
activ
intravascular
macrophag
capillari
destruct
immunolog
find
encompass
complement
human
leukocyt
antigen
hla
deposit
though
requir
diagnosi
antibodymedi
reject
author
also
perform
screen
antihla
antibodi
posttransplant
antibodi
check
month
transplant
annual
presenc
high
level
donorspecif
antihla
antibodi
usual
median
fluoresc
intens
standard
fluoresc
intens
consid
potenti
cytotox
may
merit
chang
treatment
depend
clinic
situat
although
perform
endomyocardi
biopsi
straightforward
morbid
associ
invas
procedur
led
attempt
identifi
mean
diagnos
reject
allomap
express
signatur
deriv
peripher
blood
mononuclear
cell
may
predict
cellular
reject
clinic
trial
patient
month
posttranspl
allomap
geneexpress
profil
noninferior
biopsi
diagnosi
cellular
reject
howev
allomap
yet
wide
incorpor
clinic
practic
mainli
concern
random
trial
protocol
low
event
rate
clinic
trial
limit
gener
use
recent
random
control
trial
allomap
first
month
transplant
also
demonstr
noninferior
biopsi
howev
problem
allomap
test
includ
inabl
detect
antibodymedi
reject
fact
test
use
within
first
day
transplant
use
patient
receiv
blood
transfus
hematopoiet
growth
factor
affect
leukocyt
granulocytecoloni
stimul
factor
within
past
day
thu
widespread
use
allomap
instead
endomyocardi
biopsi
like
requir
clinic
use
experi
adopt
transplant
center
manag
reject
proce
stepwis
fashion
base
sever
reject
detect
biopsi
patient
present
fig
reject
often
occur
earli
transplant
treatment
similar
regardless
time
present
grade
r
cellular
reject
find
suspici
antibodymedi
reject
absenc
clinic
hemodynam
compromis
gener
merit
intervent
manag
controversi
present
center
treatment
may
proceed
higher
level
reject
describ
next
seriou
find
biopsi
includ
grade
r
higher
cellular
reject
higher
antibodymedi
reject
requir
treatment
intens
treatment
depend
patient
present
patient
symptom
heart
failur
normal
left
ventricular
eject
fraction
treatment
option
includ
oral
intraven
puls
steroid
target
higher
level
immunosuppress
medic
switch
cyclosporin
tacrolimu
switch
mmf
psi
given
equival
success
intraven
oral
corticosteroid
therapi
treatment
asymptomat
cellular
reject
outpati
cours
oral
corticosteroid
often
firstlin
treatment
asymptomat
cellular
reject
asymptomat
antibodymedi
reject
challeng
recent
studi
indic
may
associ
poor
outcom
unclear
whether
treatment
affect
outcom
author
institut
patient
receiv
oral
corticosteroid
bolu
consider
intraven
immun
globulin
close
monitor
donorspecif
hla
antibodi
patient
reduc
eject
fraction
echocardiogram
treatment
aggress
reduct
eject
fraction
absenc
biopsi
evid
reject
may
treat
intraven
corticosteroid
cytolyt
therapi
antithymocyt
globulin
addit
adjust
immunosuppress
medic
outlin
earlier
evid
higher
patient
also
receiv
intraven
immun
globulin
donorspecif
antihla
antibodi
present
set
antibodymedi
reject
decreas
eject
fraction
patient
may
receiv
steroid
bolu
taper
intens
therapi
intraven
immun
globulin
rituximab
bortezomib
final
patient
present
cardiogen
shock
result
biopsi
less
import
aggress
empir
treatment
includ
intraven
corticosteroid
cytolyt
therapi
plasmapheresi
intraven
immun
globulin
intraven
heparin
patient
often
thrombot
occlus
cardiac
microvasculatur
postmortem
examin
hemodynam
support
intraaort
balloon
counterpuls
even
extracorpor
membran
oxygen
protocol
treatment
reject
vari
transplant
center
random
trial
compar
strategi
howev
given
rel
small
number
heart
transplant
perform
intern
rel
rariti
reject
trial
would
difficult
conduct
power
assess
differ
treatment
strategi
thu
clinician
one
must
reli
experi
judgment
formul
treatment
plan
maxim
benefit
minim
toxic
therapi
wherea
cellular
reject
often
success
treat
corticosteroid
cytolyt
therapi
result
resolut
heart
failur
normal
eject
fraction
manag
antibodymedi
reject
often
complic
patient
often
persist
reduct
eject
fraction
restrict
physiolog
lead
recurr
symptom
heart
failur
acceler
progress
transplant
coronari
arteri
diseas
manag
patient
persist
drop
eject
fraction
treatment
symptomat
reject
well
establish
fig
author
often
reli
therapi
reduc
level
donorspecif
antihla
antibodi
includ
rituximab
bortezomib
well
photopheresi
alter
function
cell
small
case
seri
therapi
shown
benefit
although
often
patient
go
requir
redo
transplant
incid
prognosi
incid
cardiac
allograft
vasculopathi
cav
vari
wide
owe
differ
definit
diseas
patient
popul
one
largest
cohort
studi
angiogram
perform
patient
institut
angiograph
signific
cav
note
patient
year
recent
studi
although
heart
transplant
recipi
develop
cav
year
substanti
increas
incid
thereaft
develop
diseas
year
cav
occur
soon
year
transplant
earli
diseas
aggress
associ
wors
prognosi
one
studi
angiograph
diseas
increas
risk
major
cardiac
event
increas
risk
death
followup
patient
without
appar
angiograph
epicardi
diseas
microvascular
abnorm
may
present
associ
advers
outcom
given
denerv
transplant
heart
patient
experi
typic
angina
present
cav
differ
nontranspl
cav
outlin
tabl
howev
electrocardiograph
chang
myocardi
infarct
may
atyp
owe
baselin
abnorm
heterogen
diseas
result
diffus
vasculopathi
gener
atyp
present
often
lead
lower
util
revascular
therapi
consequ
wors
outcom
includ
heart
failur
arrhythmia
sudden
death
reason
routin
surveil
angiographi
perform
cardiac
transplant
recipi
usual
interv
detect
cardiac
allograft
vasculopathi
cav
usual
beyond
therapeut
intervent
time
symptom
develop
surveil
essenti
monitor
develop
cav
coronari
angiographi
remain
mainstay
cav
detect
although
limit
coronari
angiographi
reli
abil
compar
normal
segment
vessel
diseas
segment
diffus
natur
cav
often
result
underestim
diseas
refer
segment
wherebi
normal
diamet
vessel
assess
comparison
prior
studi
may
help
requir
use
angiograph
protocol
studi
avoid
confound
technic
factor
angiograph
project
magnif
intravascular
ultrasonographi
ivu
current
techniqu
offer
crosssect
imag
coronari
vessel
wall
compar
histolog
section
fig
intim
area
quantit
assess
detect
even
earli
plaqu
burden
sequenti
imag
usual
obtain
cathet
pull
back
determin
extent
diseas
along
vessel
wall
sever
studi
ivu
sensit
angiographi
detect
cav
ivu
also
prognost
valu
progress
intim
thicken
greater
mm
first
year
heart
transplant
associ
increas
risk
death
develop
angiograph
cav
year
transplant
nevertheless
ivu
sever
limit
highli
invas
requir
anticoagul
use
expens
singleus
cathet
evalu
mainli
limit
major
epicardi
vessel
clinic
appar
cav
associ
poor
prognosi
prevent
import
strategi
box
agent
use
treatment
prevent
convent
atherosclerosi
use
cav
aspirin
given
establish
role
nontranspl
coronari
diseas
control
hypertens
hyperlipidemia
paramount
coenzym
reductas
inhibitor
particularli
import
also
prevent
allograft
reject
psi
also
show
signific
promis
reduc
progress
intim
thicken
ivu
clinic
signific
cav
appar
percutan
coronari
intervent
pci
success
focal
diseas
although
restenosi
common
transplant
set
drugelut
stent
may
help
restenosi
rate
continu
higher
similar
intervent
nontranspl
popul
evid
date
pci
alter
prognosi
cav
mani
patient
signific
diseas
asymptomat
intervent
often
present
dilemma
patient
multivessel
focal
diseas
adequ
distal
target
vessel
may
candid
surgic
revascular
coronari
arteri
bypass
graft
cabg
efficaci
difficult
determin
rel
small
number
report
reflect
mani
patient
adequ
target
preferenti
use
pci
retransplant
may
consider
mani
patient
advanc
cav
amen
pci
cabg
retransplant
patient
surviv
compar
patient
undergo
first
transplant
increas
incid
cav
second
donor
heart
scarciti
donor
heart
howev
creat
ethic
dilemma
argu
better
maxim
distribut
organ
rather
alloc
organ
individu
other
contend
patient
need
second
transplant
consid
basi
evalu
first
transplant
immunosuppress
therapi
cardiac
transplant
recipi
risk
infect
gener
predict
pattern
base
time
transplant
summari
infect
risk
provid
fig
antimicrobi
prophylaxi
summar
tabl
acut
reject
monitor
immun
statu
infect
risk
remain
problemat
problem
led
sever
attempt
investig
monitor
assay
none
well
valid
present
current
standard
approach
accur
assess
risk
infect
transplant
recipi
howev
immunemonitor
assay
immuknow
cylex
columbia
md
perform
peripher
blood
measur
adenosin
triphosph
atp
releas
activ
lymphocyt
may
offer
guidanc
profoundli
immunosuppress
patient
largest
studi
date
heart
transplant
recipi
averag
tcell
immun
function
tcif
score
significantli
lower
patient
develop
episod
infect
within
month
measur
compar
steadyst
patient
tcif
score
less
ng
atpml
associ
futur
infect
author
use
inform
tailor
immunosuppress
patient
infect
tcif
score
less
ng
atpml
immunosuppress
reduc
either
decreas
dose
mmf
target
lower
drug
level
calcineurin
inhibitor
psi
tcif
score
ng
atpml
patient
adequ
level
immunosuppress
tcif
score
greater
ng
atpml
patient
may
underimmunosuppress
mmf
dose
may
increas
high
drug
level
calcineurin
inhibitor
psi
may
target
malign
one
common
caus
mortal
heart
transplant
recipi
ishlt
registri
demonstr
cumul
risk
malign
year
mostli
attribut
skin
cancer
detail
discuss
posttranspl
malign
beyond
scope
review
howev
critic
point
treatment
malign
prevent
author
encourag
heart
transplant
recipi
institut
undergo
routin
health
mainten
screen
primari
care
physician
addit
patient
instruct
use
sun
protect
establish
care
dermatologist
routin
skin
examin
initi
approach
malign
reduct
immunosuppress
switch
patient
newli
diagnos
malign
psi
sirolimu
everolimu
instead
calcineurin
inhibitor
mmf
possibl
protect
effect
psi
malign
gener
medic
manag
essenti
heart
transplant
recipi
receiv
regular
care
internist
routin
health
mainten
patient
requir
gener
medic
surveil
nontranspl
patient
includ
ageappropri
cancer
screen
malign
cervix
breast
colon
prostat
internist
may
also
manag
longterm
complic
heart
transplant
recipi
includ
renal
dysfunct
hypertens
dyslipidemia
diabet
osteoporosi
gout
howev
essenti
instruct
transplant
recipi
inform
transplant
center
new
medic
recommend
internist
may
unforeseen
interact
monitor
tabl
last
decad
cardiac
transplant
becom
prefer
therapi
select
patient
endstag
heart
diseas
improv
immunosuppress
posttranspl
care
result
substanti
decreas
acut
allograft
reject
previous
led
significantli
limit
surviv
transplant
recipi
howev
major
impedi
longterm
allograft
surviv
exist
includ
reject
infect
cav
malign
nevertheless
care
balanc
immunosuppress
therapi
vigil
surveil
complic
advanc
longterm
outcom
heart
transplant
recipi
expect
decad
come
